www pharmexec com 42 may 2003 pharmaceutical executive special report l j sellers senior editor ca thy sel tzer 43 1 pfizer 2 glaxosmithkline 3 merck 4 astrazeneca 5aventis 6 johnson & 7novartis 8 bristol myers squibb 9 pharmacia 10 wyeth 11 eli lilly 12 roche 13 abbott labs 14 schering plough 15 sanofi synthelabo 16 boehringer ingelheim 17 takeda 18 ag 19 bayer 20 amgen 21 sankyo 22 akzo nobel 23 eisai 24 yamanouchi 25 kgaa 26 novo nordisk 27 baxter 28 shionogi 29 daiichi 30 teva 31 fujisawa 32 genentech 33 solvay 34 purdue pharma 35 altana 36 otsuka 37 tanabe seiyaku 38 forest 39 serono 40 allergan 41 watson kyowa king 44 biogen 45 ono 46 elan 47 alcon 48 schwarz 49 3m 50 genzyme to tal product sales grew around 430 billion but some companies including and lost patent coverage on their blockbusters had shrinking revenues slid a couple of points each in the ranking which still made list with actually 639 mil lion for year dropped from
